“ImmunogenX” (a subsidiary of Immunogenics LLC) is a clinical-stage company founded in 2013 and supported by a team of world renowned scientists and collaborators. ImmunogenX was formed to address critical needs for individuals with suspected or diagnosed celiac disease.
Our research efforts are focused on therapy, disease management, and food safety. The only current recourse for an individual with celiac disease is a lifelong adherence to a gluten-free diet (GFD). A first area of development is a therapy for the treatment of patients exercising a diligent GFD. Latiglutenase is a digestive enzyme that degrades unintended ingestion of gluten in the body as an adjunct to a GFD. A second area of development involves a method of monitoring intestinal villi atrophy by measuring the level of a drug metabolite that is strongly dependent on the villi health. Even on a GFD the recovery of celiac intestinal damage is a slow process for which there is currently no effective means to monitoring improvement. A third area of development is based on our research that has greatly expanded on the knowledge of gluten toxic peptide epitopes in wheat, barley and rye and allows far more accurate and sensitive measures of the gluten content in food.
Scientific Advisory Board
Dr. Murray is Professor of Medicine and Immunology and a Consultant Gastroenterologist in the Division of Gastroenterology and Hepatology at the Mayo Clinic, Rochester, Minnesota. He received his medical training in Ireland and GI training at the University of Iowa, where he founded the celiac disease clinic in 1992. In 1998 he joined the staff of the Mayo Clinic, where he has a large clinical practice focused largely on celiac disease. In addition, he runs the celiac disease research and clinical program that focuses on disease epidemiology and complications and mouse models of gluten sensitivity. His programs are supported by the NIH. He is a senior associate editor of American Journal Of Gastroenterology as well as an expert reviewer for many scientific journals and has published over 170 scientific articles.
Dr. Green is the Director of The Celiac Disease Center at Columbia University. He is a Professor of Clinical Medicine at the College of Physicians and Surgeons, Columbia University and Attending Physician at the New York-Presbyterian Hospital. Dr. Green received his medical degree from University of Sydney, Australia. After completing his Residency and GI fellowship in Sydney he became a Research fellow at Harvard Medical School and in the Gastroenterology Department at the Beth Israel Hospital in Boston. He is a Fellow of the Royal Australasian College of Physicians and the American College of Gastroenterology as well as a Member of the American Gastroenterologic Association and American Society of Gastrointestinal Endoscopy.
Dr. Kelly is Professor of Medicine at Harvard Medical School and Chief of the Herrman L. Blumgart Internal Medicine Firm, Director of Gastroenterology Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts. Dr. Kelly earned his doctor of medicine degree from Trinity College in Dublin, Ireland where he was a Foundation Scholar and recipient of numerous academic awards. He is an American Gastroenterology Association Fellow and a Fellow of the College of Gastroenterology. Dr. Kelly’s longstanding clinical and research interests are in intestinal infection and inflammation and the pathogenesis and management of celiac disease. He heads clinical, research and educational programs in celiac disease as Medical Director of the Celiac Center at BIDMC. Dr. Kelly is author on more than 100 clinical and basic research book chapters, invited reviews, and peer-reviewed publications.
Dr. Mäki is professor (emeritus) at the University of Tampere and presently research director at the Tampere University Hospital, Tampere, Finland. He has an extensive track record in celiac disease research and research leadership. Prof. Mäki’s research has been inspired by the needs of the celiac sufferers; he has also been the President of the Finnish Celiac Society. Lately Professor Mäki has been involved in novel drug trials in celiac disease and his interest is especially in outcome measures. In 2010, Professor Mäki received the Wm. K. Warren Jr. Prize in Celiac Disease in Clinical/Translational Research, San Diego, USA. Dr. Mäki is a permanent member of the Finnish Academy of Science and Letters and the President of Finland has granted him the honour of Knight, First Class, of the Order of the White Rose of Finland in 2006.
Dr. Henion is an internationally recognized leader in the field of MS and LC/MS. He has published more than 200 peer-reviewed papers. In addition to his work at Advion, Dr. Henion managed a major research laboratory at Cornell University, where he served as a professor of toxicology for more than 24 years and is now Emeritus Professor of Analytical Toxicology. Under his leadership and vision, Advion has established itself as one of the largest and most respected LC/MS contract laboratories in the world and a leader in chip-based nanoelectrospray mass spectrometry. He is the recipient of many honors and awards.
Dr. Kocken is currently VP, Quality Assurance at Nektar Therapeutics. He has over 20 years of experience in CMC, Quality Systems, Quality Assurance and Regulatory Affairs in the biopharmaceutical industry. Prior to joining Nektar Therapeutics, Dr. Kocken served as VP Regulatory Affairs and Quality for Alvine Pharmaceuticals Inc., supporting the development of investigational new drugs targeting Celiac disease. Dr. Kocken previously served as VP Quality Systems at VaxGen. Prior to his industry career, Dr. Kocken was Assistant Professor of Molecular Biology at Eindhoven University of Technology in the Netherlands. He received his Ph.D. in Chemical Technology from Eindhoven University of Technology.